Mirati Therapeutics (MRTX) has made great progress with respect to its drug adagrasib, which has already been granted Accelerated Approval from the FDA for the treatment of patients with metastatic or ...
First and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have deleterious germline or somatic BRCA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback